About > International Advisory Board
An international Advisory Board is established, and is collaborating with the project management team. In order to provide a balance of multidisciplinary skills and experience in all major fields, several EORTC QOL Group members are now members of the International PROBE Advisory Board.
Members include Dr. Henning Flechtner (Psychiatrist), Dr. Martin Taphoorn (Neurologist) and Dr. Eva Greimel (Clinical Psychologist).
The members of the NCIC are represented by Dr. Jolie Ringash (Medical Radiation Oncologist) and USA clinical groups are represented by Dr. Charles Cleeland (Eastern Cancer Oncology Group) and Carolyn Gotay PhD (Canadian Cancer Society Chair, Dpt of Health Care & Epidemiology Faculty of Medicine, University of British Columbia, Canada).
To ensure adequate worldwide utilization of the results in the Asia-Pacific region, Dr. Madeleine King (University of Sydney), is invited to collaborate as corresponding member.
Independent reviewers are evaluating progress and making recommendations (i.e. Emeritus Professor David Osoba, University of British Columbia, Canada; Dr. Bryce Reeve, Psychometrician and Program Director at the U.S. National Institutes of Health's National Cancer Institute (NCI) and Joachim Weis, Former Chair of the German Psychosocial Society).
Furthermore, to be comprehensive, an independent ethical advisor (Prof. Dr. Joseph Schmucker-von Koch, Bioethics/Medical Ethics, Institute of Philosophy, University of Regensburg) is available to help evaluate any ethical issue that may arise.
Dr. Charles S. Cleeland, PhD
Dr. Cleeland, M. D. Anderson's McCullough Professor of Cancer Research and recipient of the American Pain Society's 2002 Fordyce Clinical Investigator Award, is a leader in the area of cancer symptom epidemiology, assessment and treatment. In addition to serving as Chair of the Department of Symptom Research, he also serves as director and chair of the scientific advisory board of the American Pain Foundation and senior scientific advisor of the PAHO/WHO Collaborating Center in Supportive Cancer Care. He is a member and past president of the board of directors of the United States Cancer Pain Relief Committee and the American Pain Society.
Dr. Cleeland founded the Pain Research group in 1979 at the University of Wisconsin, and soon became an internationally recognized expert on the assessment and treatment of cancer pain. Dr. Cleeland and the Pain Research Group relocated to M. D. Anderson in 1996. In March 2002, the Pain Research Group became the Department of Symptom Research. The department integrates laboratory research to develop animal models of pain, fatigue, and cognitive impairment with descriptive research and interventional trials in patients.
His recent research, supported by the National Institutes of Health, the Department of Defense, and the American Cancer Society, includes several epidemiological studies of pain and other symptoms of cancer patients, laboratory studies of the mechanisms of pain and other symptoms, and clinical trials on pain relief skills for minority outpatients and their caregivers. His most recent efforts focus on quantifying the burden of multiple symptoms for cancer patients, identifying underlying mechanisms of cancer symptoms, and on national and international clinical trials in symptom management.
Dr. Cleeland's research is widely published. He has published numerous studies of the prevalence and severity of cancer pain, of U.S. and international symptom management practice patterns, and of patient, public and professional attitudes toward cancer pain and its treatment.
Cleeland CS & Reyes-Gibby CC. When is it Justified to Treat Symptoms? Measuring Symptom Burden. Oncology Sep 2002;16(9 Suppl 10):64-70.
Reyes-Gibby CC, Aday LA, Cleeland CS, Impact of pain on self-related health in the community-dwelling older adults. Pain 2002; 95(1-2): 75-82.
Wang XS, Giralt SA, Mendoza TR, Engstrom MC, Johnson BA, Peterson N, Broemeling LD, Cleeland CS, Clinical Factors Associated with Cancer-Related Fatigue in Patients being Treated for Leukemia and Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 2002; 20(5): 1319-1328.
Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer alfa therapy. Cancer 2002, August 15; 95(4):888-895.
Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC. Assessing Symptom Distress in Cancer: The M. D. Anderson Symptom Inventory. Cancer, October 1, 2000, Volume 89, Number 7.
Dr. Cleeland founded the Pain Research group in 1979 at the University of Wisconsin, and soon became an internationally recognized expert on the assessment and treatment of cancer pain. Dr. Cleeland and the Pain Research Group relocated to M. D. Anderson in 1996. In March 2002, the Pain Research Group became the Department of Symptom Research. The department integrates laboratory research to develop animal models of pain, fatigue, and cognitive impairment with descriptive research and interventional trials in patients.
His recent research, supported by the National Institutes of Health, the Department of Defense, and the American Cancer Society, includes several epidemiological studies of pain and other symptoms of cancer patients, laboratory studies of the mechanisms of pain and other symptoms, and clinical trials on pain relief skills for minority outpatients and their caregivers. His most recent efforts focus on quantifying the burden of multiple symptoms for cancer patients, identifying underlying mechanisms of cancer symptoms, and on national and international clinical trials in symptom management.
Dr. Cleeland's research is widely published. He has published numerous studies of the prevalence and severity of cancer pain, of U.S. and international symptom management practice patterns, and of patient, public and professional attitudes toward cancer pain and its treatment.
- Fellowship: NIH Post-Doctoral Fellow, Neuropsychology, University of Wisconsin Medical School
- PhD, Clinical Psychology (Psychopharmacology), Washington University
- BA (Honors), Wesleyan University
Cleeland CS & Reyes-Gibby CC. When is it Justified to Treat Symptoms? Measuring Symptom Burden. Oncology Sep 2002;16(9 Suppl 10):64-70.
Reyes-Gibby CC, Aday LA, Cleeland CS, Impact of pain on self-related health in the community-dwelling older adults. Pain 2002; 95(1-2): 75-82.
Wang XS, Giralt SA, Mendoza TR, Engstrom MC, Johnson BA, Peterson N, Broemeling LD, Cleeland CS, Clinical Factors Associated with Cancer-Related Fatigue in Patients being Treated for Leukemia and Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 2002; 20(5): 1319-1328.
Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer alfa therapy. Cancer 2002, August 15; 95(4):888-895.
Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC. Assessing Symptom Distress in Cancer: The M. D. Anderson Symptom Inventory. Cancer, October 1, 2000, Volume 89, Number 7.
Dr. Carolyn Gotay
Dr. Carolyn Gotay joined the University of British Columbia in 2008 as a Professor and the founding incumbent of the Canadian Cancer Society Chair in Cancer Primary Prevention. Her charge is to develop an infrastructure for primary cancer prevention that includes research, training, professional and public education, and interface with the cancer care system.
From 1992 to 2007, Dr. Gotay was a Professor at the University of Hawaii Cancer Research Center, where she directed the Prevention and Control Program. She also served as Director of the Clinical Trials Unit. She was continuously supported over this period through grant awards from the National Institutes of Health, with research projects in several areas: Studies of Cancer Survivorship; Research on Interventions to Improve Cancer Patient Quality of Life; and Research to Improve Cancer-Related Outcomes in At-Risk and Underserved Populations.
Dr. Gotay received her bachelor's degree in psychology from Duke University and her master's and doctorate degrees in psychology from the University of Maryland, College Park. She has published more than 100 scientific articles. She is a Fellow of the American Psychological Association, co-chair of the Cancer Survivorship Committee of the Southwest Oncology Group, and former chair of the state of Hawaii's Comprehensive Cancer Control Program. Dr. Gotay is the recipient of the 2001 Professorship of Survivorship Award from the Susan G. Komen Breast Cancer Foundation. She serves as a Consulting Editor for the Journal of Clinical Oncology, Associate Editor for Expert Review of Pharmacoeconomics & Outcomes Research and on the Editorial Board of the Annals of Behavioral Medicine.
From 1992 to 2007, Dr. Gotay was a Professor at the University of Hawaii Cancer Research Center, where she directed the Prevention and Control Program. She also served as Director of the Clinical Trials Unit. She was continuously supported over this period through grant awards from the National Institutes of Health, with research projects in several areas: Studies of Cancer Survivorship; Research on Interventions to Improve Cancer Patient Quality of Life; and Research to Improve Cancer-Related Outcomes in At-Risk and Underserved Populations.
Dr. Gotay received her bachelor's degree in psychology from Duke University and her master's and doctorate degrees in psychology from the University of Maryland, College Park. She has published more than 100 scientific articles. She is a Fellow of the American Psychological Association, co-chair of the Cancer Survivorship Committee of the Southwest Oncology Group, and former chair of the state of Hawaii's Comprehensive Cancer Control Program. Dr. Gotay is the recipient of the 2001 Professorship of Survivorship Award from the Susan G. Komen Breast Cancer Foundation. She serves as a Consulting Editor for the Journal of Clinical Oncology, Associate Editor for Expert Review of Pharmacoeconomics & Outcomes Research and on the Editorial Board of the Annals of Behavioral Medicine.
Dr. Henning Flechtner
Dr. Henning Flechtner was invited in January 2008 by the Minister of Science of Sachsen-Anhalt to be appointed as chair of child and adolescent psychiatry at the Otto-von-Guericke-University Magdeburg. Currently he is Associate Professor of child and adolescent psychiatry at the University of Cologne and since 2006 director of the University department of child and adolescent psychiatry of the Medical Faculty of the Otto-von-Guericke-University Magdeburg at Klinikum Magdeburg gGmbH.
He spent a 6 year training period in medical oncology and a full training in child psychiatry, adult psychiatry and psychotherapeutic/ psychosomatic medicine and received the board certificates for child and adolescent psychiatry, psychotherapy and psychosomatic medicine. He has been a member of the EORTC Quality of Life Group since 1985 and was involved in the development of the original EORTC QLQ C30 instrument. For many years he has served as a liaison officer to the EORTC Lymphoma Group and coordinated the quality of life trials within this group. Since 1995 he is chairing the quality of life committee of the German Hodgkin Study Group (GHSG) and is coordinating the quality of life research within the GHSG.
His main research interests recently include quality of life in psychiatric disciplines (his PhD thesis was devoted to the development of an instrument to assess the quality of life of child and adolescent psychiatric patients), fatigue assessment, and survivorship issues in lymphoma patients.
He has authored and co-authored numerous peer reviewed publications in psycho-oncology and quality of life research.
He spent a 6 year training period in medical oncology and a full training in child psychiatry, adult psychiatry and psychotherapeutic/ psychosomatic medicine and received the board certificates for child and adolescent psychiatry, psychotherapy and psychosomatic medicine. He has been a member of the EORTC Quality of Life Group since 1985 and was involved in the development of the original EORTC QLQ C30 instrument. For many years he has served as a liaison officer to the EORTC Lymphoma Group and coordinated the quality of life trials within this group. Since 1995 he is chairing the quality of life committee of the German Hodgkin Study Group (GHSG) and is coordinating the quality of life research within the GHSG.
His main research interests recently include quality of life in psychiatric disciplines (his PhD thesis was devoted to the development of an instrument to assess the quality of life of child and adolescent psychiatric patients), fatigue assessment, and survivorship issues in lymphoma patients.
He has authored and co-authored numerous peer reviewed publications in psycho-oncology and quality of life research.
Dr. Eva Greimel
Dr. Eva Greimel received her Ph.D. in psychology from the Karl-Franzens University Graz, Austria.
She is Associated Professor in Medical Psychology and Behavioural Sciences at the Medical University Graz. Her clinical experience at the University Hospital, Department of Gynecology focuses on female health issues especially related to gynaecological cancer.
During her postdoctoral fellowship at University of California Los Angeles (UCLA) Dr. Greimel attended a Health-related Quality of Life Training Program and has worked extensively on numerous research and clinical projects in psychosocial oncology.
She has been a member of the EORTC Quality of Life Group for many years where she has coordinated the development of quality of life modules for gynaecologic oncology. Her research interests include instrument development, cross-cultural validation, clinical application and implementation of patient reported outcome measures in clinical research settings. Dr. Greimel has broad international experience in various cancer clinical trial groups.
She has authored and co-authored numerous peer reviewed publications in psycho-oncology and quality of life research.
She is Associated Professor in Medical Psychology and Behavioural Sciences at the Medical University Graz. Her clinical experience at the University Hospital, Department of Gynecology focuses on female health issues especially related to gynaecological cancer.
During her postdoctoral fellowship at University of California Los Angeles (UCLA) Dr. Greimel attended a Health-related Quality of Life Training Program and has worked extensively on numerous research and clinical projects in psychosocial oncology.
She has been a member of the EORTC Quality of Life Group for many years where she has coordinated the development of quality of life modules for gynaecologic oncology. Her research interests include instrument development, cross-cultural validation, clinical application and implementation of patient reported outcome measures in clinical research settings. Dr. Greimel has broad international experience in various cancer clinical trial groups.
She has authored and co-authored numerous peer reviewed publications in psycho-oncology and quality of life research.
Dr. Madeleine King
Dr. Madeleine King leads biostatistics and outcomes research at the Centre for Health Economics, Research & Evaluation (CHERE), University of Technology (UTS), Sydney, where she is Associate Professor in Health Services Research. She holds a PhD and Graduate Diploma in Medical Statistics from the University of Newcastle, NSW, and a Bachelor of Science with First Class Honours from the University of Sydney.
Madeleine's research experience covers a range of disciplines, including biostatistics, epidemiology, psychometrics, health economics and clinical research (both medical and nursing), with applications in cancer, asthma and dementia. Her interests and expertise focuses on the measurement, analysis, interpretation and application of a range of patient-reported measures, including health status, quality of life, patient/carer preferences and utility; and the design and analysis of longitudinal and cluster-randomised studies.
Madeleine is an active researcher, with many successful collaborations across academic institutions locally and internationally. She has been a chief investigator on thirteen competitively funded research grants totaling $3,955,469, two large government contracts and a small industry grant ($1,519,394) and five internal university/CRC grants ($907,400). She has a strong publication record in well regarded peer-review journals and presents, both invited and proffered papers, regularly at national and international conferences.
Madeleine's expertise in the analysis and interpretation of health-related quality of life (HRQOL) is recognised nationally and internationally. In the mid-1990's she developed interpretation guidelines for the QLQ-C30, the most widely used HRQOL questionnaire in cancer clinical trials. These guidelines were published in Quality of Life Research (1996; 5, 555-567); that paper is now cited in over 150 papers. She co-authored a book chapter titled "Interpreting QOL in individuals and groups: meaningful differences" (in Assessing Quality of Life, Fayers & Hays (Eds), Oxford University Press, 2005) and co-developed an educational workshop based on this material, which she presented with co-author Prof David Osoba at the 2003 and 2004 annual scientific meetings of the International Society for Quality of Life Research (ISOQOL) and at the Australian Health Outcomes conference in 2006. She presented earlier versions of this workshop solo at the Australian Health Outcomes conference annually from 2002 to 2005, and co-presented a workshop with a similar focus in association with the Mapi Institute for the 11th Cochrane Colloquium in 2003. Madeleine has been an invited speaker at four international HRQOL conferences: at the 2nd Turkish QOL Congress in April 2007; at the 1st Hong Kong Society of QOL conference in May 2006; and at ISOQOL's annual conferences in 2002 and 2006. She presented plenary papers at the Australian Health Outcomes Collaboration (AHOC) annual conference in 2002 and 2005, and at the Clinical Oncology Society of Australia (COSA) annual conference in 2006.
Madeleine was the first Australian elected to the Board of ISOQOL (2002-2004), and was voted President for 2007, sitting on the Executive Committee 2006-2008. She chaired ISOQOL's Scientific Program Committee in 2004 (annual conference in Hong Kong), and has championed the development of regional ISOQOL chapters in Asia, Eastern Europe, Latin America and Africa. She is a member of numerous local and national advisory committees. She has been a corresponding member of the EORTC QOL Group since 2001, and is currently collaborating with several of the Group's members. Her teaching focuses on research methods coursework for, and supervision of, postgraduate research students.
Madeleine's research experience covers a range of disciplines, including biostatistics, epidemiology, psychometrics, health economics and clinical research (both medical and nursing), with applications in cancer, asthma and dementia. Her interests and expertise focuses on the measurement, analysis, interpretation and application of a range of patient-reported measures, including health status, quality of life, patient/carer preferences and utility; and the design and analysis of longitudinal and cluster-randomised studies.
Madeleine is an active researcher, with many successful collaborations across academic institutions locally and internationally. She has been a chief investigator on thirteen competitively funded research grants totaling $3,955,469, two large government contracts and a small industry grant ($1,519,394) and five internal university/CRC grants ($907,400). She has a strong publication record in well regarded peer-review journals and presents, both invited and proffered papers, regularly at national and international conferences.
Madeleine's expertise in the analysis and interpretation of health-related quality of life (HRQOL) is recognised nationally and internationally. In the mid-1990's she developed interpretation guidelines for the QLQ-C30, the most widely used HRQOL questionnaire in cancer clinical trials. These guidelines were published in Quality of Life Research (1996; 5, 555-567); that paper is now cited in over 150 papers. She co-authored a book chapter titled "Interpreting QOL in individuals and groups: meaningful differences" (in Assessing Quality of Life, Fayers & Hays (Eds), Oxford University Press, 2005) and co-developed an educational workshop based on this material, which she presented with co-author Prof David Osoba at the 2003 and 2004 annual scientific meetings of the International Society for Quality of Life Research (ISOQOL) and at the Australian Health Outcomes conference in 2006. She presented earlier versions of this workshop solo at the Australian Health Outcomes conference annually from 2002 to 2005, and co-presented a workshop with a similar focus in association with the Mapi Institute for the 11th Cochrane Colloquium in 2003. Madeleine has been an invited speaker at four international HRQOL conferences: at the 2nd Turkish QOL Congress in April 2007; at the 1st Hong Kong Society of QOL conference in May 2006; and at ISOQOL's annual conferences in 2002 and 2006. She presented plenary papers at the Australian Health Outcomes Collaboration (AHOC) annual conference in 2002 and 2005, and at the Clinical Oncology Society of Australia (COSA) annual conference in 2006.
Madeleine was the first Australian elected to the Board of ISOQOL (2002-2004), and was voted President for 2007, sitting on the Executive Committee 2006-2008. She chaired ISOQOL's Scientific Program Committee in 2004 (annual conference in Hong Kong), and has championed the development of regional ISOQOL chapters in Asia, Eastern Europe, Latin America and Africa. She is a member of numerous local and national advisory committees. She has been a corresponding member of the EORTC QOL Group since 2001, and is currently collaborating with several of the Group's members. Her teaching focuses on research methods coursework for, and supervision of, postgraduate research students.
Dr. Bryce Reeve
Dr. Reeve is a Psychometrician and Program Director at the U.S. National Institutes of Health's National Cancer Institute (NCI), where he has worked since 2000. At NCI, he directs an active program to enhance the use of patient-reported outcomes (PROs; including health-related quality of life (HRQOL) and patient experiences with healthcare) in clinical research and practice to improve the quality of care for both pediatric and adult cancer patients. With a degree in quantitative psychology from the University of North Carolina at Chapel Hill, his work at NCI is focused on enhancing PRO measures with innovative psychometric methodologies and integrating PRO data in cancer research and healthcare delivery to inform decision-making.
Dr. Reeve serves as a NIH Science Officer on the Patient-Reported Outcomes Measurement Information System (PROMIS) Network. The PROMIS Network is in the process of building a public domain Web-based resource to dynamically administer, collect, and report data on key HRQOL domains relevant to a variety of chronic diseases. In 2004, he organized an international conference on applying item response theory and computerized-adaptive testing methodology to enhance HRQOL assessment. This effort led to the publication of a special issue in Quality of Life Research on Applying Item Response Theory to Enhance Health Outcomes Measurement, co-edited by Dr. Reeve.
In September 2006, he organized a NCI-sponsored conference examining the value and challenges of integrating HRQOL in cancer clinical trials. This effort led to the publication of a special issue in Journal of Clinical Oncology on Patient-Reported Outcomes Assessment in Cancer Trials, co-edited by Dr. Reeve.
Dr. Reeve was elected and now currently serves on the Board of Directors of the International Society for Quality of Life Research (ISOQOL). He also serves on NCI's Symptom Management and Health-Related Quality of Life Steering Committee and the Steering Committee of Assessing the Symptoms of Cancer using Patient-Reported Outcomes.
Dr. Reeve serves as a NIH Science Officer on the Patient-Reported Outcomes Measurement Information System (PROMIS) Network. The PROMIS Network is in the process of building a public domain Web-based resource to dynamically administer, collect, and report data on key HRQOL domains relevant to a variety of chronic diseases. In 2004, he organized an international conference on applying item response theory and computerized-adaptive testing methodology to enhance HRQOL assessment. This effort led to the publication of a special issue in Quality of Life Research on Applying Item Response Theory to Enhance Health Outcomes Measurement, co-edited by Dr. Reeve.
In September 2006, he organized a NCI-sponsored conference examining the value and challenges of integrating HRQOL in cancer clinical trials. This effort led to the publication of a special issue in Journal of Clinical Oncology on Patient-Reported Outcomes Assessment in Cancer Trials, co-edited by Dr. Reeve.
Dr. Reeve was elected and now currently serves on the Board of Directors of the International Society for Quality of Life Research (ISOQOL). He also serves on NCI's Symptom Management and Health-Related Quality of Life Steering Committee and the Steering Committee of Assessing the Symptoms of Cancer using Patient-Reported Outcomes.
Dr. Jolie Ringash
Dr. Ringash is an associate professor of Radiation Oncology at the University of Toronto, and a staff radiation oncologist at the Princess Margaret Hospital. She is cross appointed to the Department of Health Policy, Management and Evaluation at the University of Toronto, where she serves as Associate Programme Director for the graduate programme in Clinical Epidemiology.
Dr. Ringash obtained her BSc in Chemistry at McMaster University in 1990, and went on to obtain her MD in 1993. She trained in Radiation Oncology at McMaster University. After obtaining her FRCP(C) in 1997, she was a clinical fellow in radiation oncology at the Princess Margaret Hospital, and simultaneously completed her MSc in Clinical Epidemiology at the University of Toronto in 1999.
Dr. Ringash is currently co-Chair of the Quality of Life committee at the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Her research interests include the quality of life of cancer patients, clinical decision making, and the treatment of head and neck and GI malignancies. She has served as Quality of Life (QOL) coordinator on a major international clinical trial in head and neck cancer for the Trans-Tasman Radiation Oncology Group and will coordinate an upcoming trial for the NCIC-CTG with important QOL and swallowing outcomes.
Dr. Ringash obtained her BSc in Chemistry at McMaster University in 1990, and went on to obtain her MD in 1993. She trained in Radiation Oncology at McMaster University. After obtaining her FRCP(C) in 1997, she was a clinical fellow in radiation oncology at the Princess Margaret Hospital, and simultaneously completed her MSc in Clinical Epidemiology at the University of Toronto in 1999.
Dr. Ringash is currently co-Chair of the Quality of Life committee at the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Her research interests include the quality of life of cancer patients, clinical decision making, and the treatment of head and neck and GI malignancies. She has served as Quality of Life (QOL) coordinator on a major international clinical trial in head and neck cancer for the Trans-Tasman Radiation Oncology Group and will coordinate an upcoming trial for the NCIC-CTG with important QOL and swallowing outcomes.
Dr. Martin Taphoorn
Martin Taphoorn was a medical student at the State University Leiden, where he obtained his degree as MD in 1984, followed by a residency in neurology and clinical neurophysiology at the Free University (at present: VU University) Amsterdam. Afterwards he performed clinical research in neuro-oncology and wrote his PhD thesis at the VU University Medical Center Amsterdam.
He continued his career at the University Medical Center Utrecht where he was a senior staff member at the department of neurology and also performed both preclinical and clinical research in neuro-oncology, mainly devoted to cognitive functioning and central neurotoxicity.
In 1998 he did a neuro-oncology sabbatical in MD Anderson Medical Center Houston and Memorial Sloan-Kettering New York City, for which he obtained a grant from the Dutch Cancer Society. In 2003 he moved to Medical Center Haaglanden, The Hague where he is a senior clinical neurologist and neuro-oncologist.
Since 2007 he combines the clinical work in The Hague with a professorship in neuro-oncology at the VU University Medical Center Amsterdam, in particular in the area of quality of life research.
He has published over 70 peer-reviewed papers in major neurology and cancer journals, and also is a regular reviewer for various international neurology and cancer journals. He has been successful in obtaining several grants from the Dutch Cancer Society for clinical research in neuro-oncology. He served as chairman of the Dutch Neuro-Oncology Group and as treasurer of the EORTC Brain Tumour Group.
At present he is an active member of both the EORTC Brain Tumour Group and Quality of Life Group, and president-elect of the Dutch Neurology Society. He also is member of the ESMO educational committee (neuro-oncology) and member of the editorial board for the Journal of Pharmacoeconomics & Outcomes Research. For the yearly meeting of the American Society for Neuro-Oncology, he reviews abstracts for the scientific programme.
He continued his career at the University Medical Center Utrecht where he was a senior staff member at the department of neurology and also performed both preclinical and clinical research in neuro-oncology, mainly devoted to cognitive functioning and central neurotoxicity.
In 1998 he did a neuro-oncology sabbatical in MD Anderson Medical Center Houston and Memorial Sloan-Kettering New York City, for which he obtained a grant from the Dutch Cancer Society. In 2003 he moved to Medical Center Haaglanden, The Hague where he is a senior clinical neurologist and neuro-oncologist.
Since 2007 he combines the clinical work in The Hague with a professorship in neuro-oncology at the VU University Medical Center Amsterdam, in particular in the area of quality of life research.
He has published over 70 peer-reviewed papers in major neurology and cancer journals, and also is a regular reviewer for various international neurology and cancer journals. He has been successful in obtaining several grants from the Dutch Cancer Society for clinical research in neuro-oncology. He served as chairman of the Dutch Neuro-Oncology Group and as treasurer of the EORTC Brain Tumour Group.
At present he is an active member of both the EORTC Brain Tumour Group and Quality of Life Group, and president-elect of the Dutch Neurology Society. He also is member of the ESMO educational committee (neuro-oncology) and member of the editorial board for the Journal of Pharmacoeconomics & Outcomes Research. For the yearly meeting of the American Society for Neuro-Oncology, he reviews abstracts for the scientific programme.
Dr. Joseph Schmucker von Koch
Professor Dr. Dr. Schmucker von Koch is professor of bioethics at the University of Regensburg, Germany. His academic background includes studies in the History of Medicine, the Social Sciences and Philosophy.
Professor Schmucker von Koch has been a project consultant to the Max-Delbrueck Center of Molecular Medicine in Berlin and is Deputy Chairman of the Ethics Committee of the Medical Authorities in the state of Bavaria.
For more than a decade he serves the European Commission as a scientific and ethical advisor as well as chairman and member of numerous ethics committees in the context of the various framework programs for science and technology (5th/6th and 7th framework program).
Dr. Joachim Weis
Since 1995 Member of the EORTC Quality of Life Study Group, 1999-2000 Member of the EORTC QoL Executive Commitee
Since 1998 Head of the board of the German Society of Psychooncology (German Cancer Society)
2000 to 2001 Head (interim) of the Department of Rehabilitation Psychology, Institute of Rehabilitation Sciences Humboldt University Berlin
2001 Head of the scientific commitee the 11th conference of the European Society of Psychosocial Oncology (ESPO 11) in Heidelberg Germany
Since 2001 (Founding) Member of the Board of German Fatigue Society
2003 Associate Professor at the University of Freiburg, Faculty of Behavioral Sciences
2005 Head of the German Association for Education and Training in Psychooncology (WPO)
Member of scientific societies: German Society of Psychology (Deutsche Gesellschaft für Psychologie DGfP), German Society of Medical Psychology (Deutsche Gesellschaft für Medizinpsychologie DGMP), German Cancer Society (Deutsche Krebsgesellschaft DKG), European Bone Marrow Transplantation (EBMT), International Society of Psychooncology (IPOS)
Since 1998 Head of the board of the German Society of Psychooncology (German Cancer Society)
2000 to 2001 Head (interim) of the Department of Rehabilitation Psychology, Institute of Rehabilitation Sciences Humboldt University Berlin
2001 Head of the scientific commitee the 11th conference of the European Society of Psychosocial Oncology (ESPO 11) in Heidelberg Germany
Since 2001 (Founding) Member of the Board of German Fatigue Society
2003 Associate Professor at the University of Freiburg, Faculty of Behavioral Sciences
2005 Head of the German Association for Education and Training in Psychooncology (WPO)
Member of scientific societies: German Society of Psychology (Deutsche Gesellschaft für Psychologie DGfP), German Society of Medical Psychology (Deutsche Gesellschaft für Medizinpsychologie DGMP), German Cancer Society (Deutsche Krebsgesellschaft DKG), European Bone Marrow Transplantation (EBMT), International Society of Psychooncology (IPOS)
